Malignant neoplasm of meninges, unspecified
ICD-10 C70.9 is a billable code used to indicate a diagnosis of malignant neoplasm of meninges, unspecified.
Malignant neoplasms of the meninges are tumors that arise from the protective membranes covering the brain and spinal cord. The meninges consist of three layers: the dura mater, arachnoid mater, and pia mater. C70.9 indicates a malignant neoplasm of the meninges without further specification regarding the type or location of the tumor. These tumors can be primary, originating in the meninges, or secondary, resulting from metastasis from other cancers. Symptoms may include headaches, seizures, neurological deficits, and changes in cognitive function. Imaging studies such as MRI or CT scans are essential for diagnosis, revealing mass lesions or abnormal enhancement patterns. Molecular markers, including genetic mutations and protein expressions, can aid in determining the tumor's origin and potential treatment pathways. Neurological function may be significantly impacted depending on the tumor's size and location, necessitating a multidisciplinary approach for management, including neurosurgery, radiation therapy, and chemotherapy.
Detailed neurological examination findings, imaging results, and treatment plans.
Patients presenting with headaches, seizures, or cognitive changes requiring imaging and further evaluation.
Ensure thorough documentation of neurological deficits and imaging results to support the diagnosis.
Pathology reports, molecular marker testing results, and treatment protocols.
Management of patients with known malignancies presenting with neurological symptoms.
Document the origin of the tumor if known and any treatment history to support coding.
Used when a malignant neoplasm of the meninges is surgically removed.
Operative report detailing the procedure and findings.
Neurosurgical documentation must include preoperative imaging and postoperative outcomes.
Document all relevant imaging findings, neurological assessments, and any treatment plans. Ensure clarity on whether the tumor is primary or secondary, and include any molecular marker testing results if available.
